Clinical Summary
Aria Diagnostics has expanded our LC-MSMS (Liquid Chromatography-Tandem Mass Spectrometry) urine drug confirmation panel to include the following substances:
> Lisdexamfetamine (Vyvanse)
> 7-OH Mitragynine (Kratom)
> Xylazine (Illicit – Tranq)
> Aripiprazole (Abilify)
> Levorphanol (Levo-Dromoran)
> Tizanidine (Zanaflex)
> Zopiclone (Lunesta)
> Buspirone (Buspar)
> Methocarbamol (Robaxin)
> Clonidine (Catapres)
These ten new drugs will be reported on confirmation testing results for samples received at Aria starting on Monday, August 4th, 2025.
Why We Added These Analytes
These substances were added to ensure we continue to offer testing of drugs that our providers need most. This determination came from feedback from our medical clients as well as a comprehensive industry analysis of: 1) regional prescription trends, 2) usage patterns, and 3) emerging concerns regarding misuse and abuse.
Key factors considered:
- Increasing prescription rates for several of these medications in pain management, behavioral health, and adjunctive therapies.
- Growing concerns of misuse and abuse for substances such as 7-OH Mitragynine (active metabolite of kratom), xylazine (illicit adulterant), and zopiclone (sedative-hypnotic).
- Enhanced therapeutic monitoring for medications frequently co-prescribed in pain management (e.g., lisdexamfetamine for ADHD, buspirone for anxiety, and tizanidine for muscle spasms).
- Potential for dangerous drug interactions—for instance, levorphanol, a potent opioid, and zopiclone, a non-benzodiazepine sedative, both carry significant risks when combined with other CNS depressants.
How This Benefits You & Your Patients
- Expanded risk assessment to better mitigate potential drug-drug interactions and overdose risks.
- Improved patient safety by identifying unreported substance use and medication adherence.
- Alignment with regional usage trends, ensuring that your practice stays ahead of evolving prescribing and abuse patterns.
We value our partnership in ensuring safe and effective urine drug screening. If you have any questions about these updates or would like additional insights on our data review process, please don’t hesitate to reach out.